• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

组蛋白去乙酰化酶 3-微小 RNA-串联扩增基因芯片网络在抗癌药物耐药中的作用。

Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance.

机构信息

Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chunchon 24341, Korea.

Institute of New Frontier Research, College of Medicine, Hallym University, Chunchon 24251, Korea.

出版信息

Int J Mol Sci. 2018 Dec 23;20(1):51. doi: 10.3390/ijms20010051.

DOI:10.3390/ijms20010051
PMID:30583572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6337380/
Abstract

Histone modification is associated with resistance to anti-cancer drugs. Epigenetic modifications of histones can regulate resistance to anti-cancer drugs. It has been reported that histone deacetylase 3 (HDAC3) regulates responses to anti-cancer drugs, angiogenic potential, and tumorigenic potential of cancer cells in association with cancer-associated genes (CAGE), and in particular, a cancer/testis antigen gene. In this paper, we report the roles of microRNAs that regulate the expression of HDAC3 and CAGE involved in resistance to anti-cancer drugs and associated mechanisms. In this review, roles of HDAC3-miRNAs-CAGE molecular networks in resistance to anti-cancer drugs, and the relevance of HDAC3 as a target for developing anti-cancer drugs are discussed.

摘要

组蛋白修饰与抗癌药物耐药性有关。组蛋白的表观遗传修饰可以调节抗癌药物的耐药性。据报道，组蛋白去乙酰化酶 3（HDAC3）与癌症相关基因（CAGE）一起调节抗癌药物的反应、血管生成潜力和癌细胞的致瘤潜力，特别是癌症/睾丸抗原基因。在本文中，我们报告了调节与抗癌药物耐药性相关的 HDAC3 和 CAGE 表达的 microRNAs 的作用及其相关机制。在这篇综述中，讨论了 HDAC3-miRNAs-CAGE 分子网络在抗癌药物耐药性中的作用，以及 HDAC3 作为抗癌药物开发靶点的相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/0805bf16da15/ijms-20-00051-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/59bd71b2e2d5/ijms-20-00051-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/29f78b24209d/ijms-20-00051-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/5590540768e6/ijms-20-00051-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/546b9ff3f941/ijms-20-00051-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/0e182ed02c4a/ijms-20-00051-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/37f292ddc82b/ijms-20-00051-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/af5cb9ed3889/ijms-20-00051-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/0805bf16da15/ijms-20-00051-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/59bd71b2e2d5/ijms-20-00051-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/29f78b24209d/ijms-20-00051-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/5590540768e6/ijms-20-00051-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/546b9ff3f941/ijms-20-00051-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/0e182ed02c4a/ijms-20-00051-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/37f292ddc82b/ijms-20-00051-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/af5cb9ed3889/ijms-20-00051-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d08/6337380/0805bf16da15/ijms-20-00051-g008.jpg

相似文献

1
Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance.组蛋白去乙酰化酶 3-微小 RNA-串联扩增基因芯片网络在抗癌药物耐药中的作用。
Int J Mol Sci. 2018 Dec 23;20(1):51. doi: 10.3390/ijms20010051.
2
miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.微小RNA-326-组蛋白去乙酰化酶-3反馈环调节对抗癌药物的侵袭、致瘤及血管生成反应。
J Biol Chem. 2014 Oct 3;289(40):28019-39. doi: 10.1074/jbc.M114.578229. Epub 2014 Aug 19.
3
Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs.组蛋白去乙酰化酶-3/CAGE轴靶向表皮生长因子受体信号传导并调节对抗癌药物的反应。
Mol Cells. 2016 Mar;39(3):229-41. doi: 10.14348/molcells.2016.2244. Epub 2016 Feb 16.
4
miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.微小RNA-217与癌症相关基因（CAGE）形成反馈回路，并通过表皮生长因子受体（EGFR）和人表皮生长因子受体2（HER2）调节对抗癌药物的反应。
Oncotarget. 2016 Mar 1;7(9):10297-321. doi: 10.18632/oncotarget.7185.
5
miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs.miR-200b 和癌症/睾丸抗原 CAGE 形成反馈回路，调节癌细胞系对微管靶向药物的侵袭、致瘤和血管生成反应。
J Biol Chem. 2013 Dec 20;288(51):36502-18. doi: 10.1074/jbc.M113.502047. Epub 2013 Oct 30.
6
miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3.微小RNA-335靶向SIAH2并通过增加组蛋白去乙酰化酶3的表达赋予对抗癌药物的敏感性。
Mol Cells. 2015 Jun;38(6):562-72. doi: 10.14348/molcells.2015.0051. Epub 2015 May 22.
7
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.表观遗传药物作为癌症治疗中的多效性药物：生物分子方面及临床应用
J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066.
8
miR-30a Regulates the Expression of CAGE and p53 and Regulates the Response to Anti-Cancer Drugs.微小RNA-30a调控CAGE和p53的表达并调节对抗癌药物的反应。
Mol Cells. 2016 Apr 30;39(4):299-309. doi: 10.14348/molcells.2016.2242. Epub 2016 Feb 25.
9
The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1.五肽甘氨酸-苏氨酸-甘氨酸-赖氨酸-苏氨酸通过抑制CAGE与GSK3β的结合以及降低细胞周期蛋白D1的表达，赋予对抗癌药物的敏感性。
Oncotarget. 2017 Feb 21;8(8):13632-13651. doi: 10.18632/oncotarget.14621.
10
Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs.微管蛋白β3作为HDAC3的靶点并介导对微管靶向药物的抗性。
Mol Cells. 2015 Aug;38(8):705-14. doi: 10.14348/molcells.2015.0086. Epub 2015 Jul 1.

引用本文的文献

1
HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization.HDAC3：免疫治疗致敏中的多面调节因子
Vaccines (Basel). 2025 Feb 13;13(2):182. doi: 10.3390/vaccines13020182.
2
miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53.miR-429通过DDX53抑制子宫内膜癌进展和耐药性。
J Pers Med. 2023 Aug 25;13(9):1302. doi: 10.3390/jpm13091302.
3
Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers.癌症/睾丸抗原：消化道肿瘤有前途的免疫治疗靶点。

本文引用的文献

1
Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.组蛋白去乙酰化酶 3 通过信号转导子和转录激活子 3 信号通路促进肝脏再生和肝癌细胞增殖。
Cell Death Dis. 2018 Mar 14;9(3):398. doi: 10.1038/s41419-018-0428-x.
2
I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53.I-7ab 通过靶向 HDAC3 和促进 p53 乙酰化来抑制三阴性乳腺癌细胞的生长。
Biomed Pharmacother. 2018 Mar;99:220-226. doi: 10.1016/j.biopha.2018.01.063.
3
Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis.
Front Immunol. 2023 Jun 16;14:1190883. doi: 10.3389/fimmu.2023.1190883. eCollection 2023.
4
Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer.癌症睾丸抗原的生物学特性及其在癌症治疗中的意义。
Cells. 2023 Mar 17;12(6):926. doi: 10.3390/cells12060926.
5
Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics.miR-200 家族作为抗癌治疗靶点的潜力。
Int J Mol Sci. 2022 May 24;23(11):5881. doi: 10.3390/ijms23115881.
6
Characterization of Histone Deacetylase Mechanisms in Cancer Development.癌症发展过程中组蛋白去乙酰化酶机制的表征
Front Oncol. 2021 Jul 29;11:700947. doi: 10.3389/fonc.2021.700947. eCollection 2021.
7
Upregulation of microRNA-181a-5p increases the sensitivity of HS578T breast cancer cells to cisplatin by inducing vitamin D receptor-mediated cell autophagy.微小RNA-181a-5p的上调通过诱导维生素D受体介导的细胞自噬增加了HS578T乳腺癌细胞对顺铂的敏感性。
Oncol Lett. 2021 Apr;21(4):247. doi: 10.3892/ol.2021.12508. Epub 2021 Feb 3.
8
MiR-1254 and regulates oxaliplatin resistance in human colorectal cancer cells.MiR-1254与人类结肠癌细胞中奥沙利铂耐药性的调节有关。 （原英文句子存在语病，正确表述可能是“MiR-1254 regulates oxaliplatin resistance in human colorectal cancer cells.” ，翻译为“MiR-1254调节人类结肠癌细胞中的奥沙利铂耐药性。” ） 按照提供的原文翻译如上。
Am J Transl Res. 2021 Jan 15;13(1):183-196. eCollection 2021.
9
miRNA-Based Feature Classifier Is Associated with Tumor Mutational Burden in Head and Neck Squamous Cell Carcinoma.基于 miRNA 的特征分类器与头颈部鳞状细胞癌的肿瘤突变负担相关。
Biomed Res Int. 2020 Dec 9;2020:1686480. doi: 10.1155/2020/1686480. eCollection 2020.
10
Exosomal MicroRNAs as Mediators of Cellular Interactions Between Cancer Cells and Macrophages.外泌体 microRNAs 作为癌细胞与巨噬细胞间细胞相互作用的介质。
Front Immunol. 2020 Jun 11;11:1167. doi: 10.3389/fimmu.2020.01167. eCollection 2020.
组蛋白去乙酰化酶3（HDAC3）的下调通过诱导细胞凋亡抑制胆管癌的生长。
Oncotarget. 2017 Jul 28;8(59):99402-99413. doi: 10.18632/oncotarget.19660. eCollection 2017 Nov 21.
4
Acetylation and deacetylation in cancer stem-like cells.癌症干细胞样细胞中的乙酰化与去乙酰化
Oncotarget. 2017 Jul 11;8(51):89315-89325. doi: 10.18632/oncotarget.19167. eCollection 2017 Oct 24.
5
Cancer stem cells revisited.癌症干细胞再探。
Nat Med. 2017 Oct 6;23(10):1124-1134. doi: 10.1038/nm.4409.
6
Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.三阴性乳腺癌细胞中 JNK 的 HDAC3 磷酸化的差异决定了 HDAC 抑制剂的结合和选择性。
Cell Chem Biol. 2017 Nov 16;24(11):1356-1367.e8. doi: 10.1016/j.chembiol.2017.08.015. Epub 2017 Sep 21.
7
DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2.DDX53通过与SOX-2结合来调控癌症干细胞样特性。
Mol Cells. 2017 May 31;40(5):322-330. doi: 10.14348/molcells.2017.0001. Epub 2017 May 2.
8
The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1.五肽甘氨酸-苏氨酸-甘氨酸-赖氨酸-苏氨酸通过抑制CAGE与GSK3β的结合以及降低细胞周期蛋白D1的表达，赋予对抗癌药物的敏感性。
Oncotarget. 2017 Feb 21;8(8):13632-13651. doi: 10.18632/oncotarget.14621.
9
Overexpression of caveolin-1 reduces Taxol resistance in human osteosarcoma cells by attenuating PI3K-Akt-JNK dependent autophagy.小窝蛋白-1的过表达通过减弱PI3K-Akt-JNK依赖性自噬降低人骨肉瘤细胞对紫杉醇的耐药性。
Exp Ther Med. 2016 Nov;12(5):2815-2822. doi: 10.3892/etm.2016.3713. Epub 2016 Sep 16.
10
CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.CBX4 通过募集 HDAC3 到结直肠癌 Runx2 启动子抑制转移。
Cancer Res. 2016 Dec 15;76(24):7277-7289. doi: 10.1158/0008-5472.CAN-16-2100. Epub 2016 Nov 18.